Trial Profile
Randomized Trial of Intravitreous Aflibercept Versus Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Jul 2022
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms DRCR AC
- 14 Jul 2022 Primary endpoint (Mean Change in Visual Acuity) has not been met, according to Results published in the New England Journal of Medicine.
- 14 Jul 2022 Results published in the New England Journal of Medicine
- 19 Jan 2022 Status changed from active, no longer recruiting to completed.